Zobrazeno 1 - 10
of 236
pro vyhledávání: '"Johanna A. Kremer Hovinga"'
Publikováno v:
Frontiers in Pediatrics, Vol 12 (2024)
The cornerstone treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP) in children is a combination of therapeutic plasma exchange (TPE), corticosteroids, and rituximab. Caplacizumab is an anti-von Willebrand factor (VWF) NANOBODY m
Externí odkaz:
https://doaj.org/article/860ad958c5fd4a269d1dedd3d878ec64
Autor:
Giancarlo Castaman, Flora Peyvandi, Johanna A. Kremer Hovinga, Roger E.G. Schutgens, Susan Robson, Katya Moreno, Víctor Jiménez-Yuste
Publikováno v:
TH Open, Vol 08, Iss 01, Pp e42-e54 (2024)
Background Guidelines surrounding emicizumab prophylaxis and perioperative treatment for people with hemophilia A (PwHA) with factor (F)VIII inhibitors undergoing surgeries are limited. The phase IIIb multicenter, single-arm STASEY study evaluated sa
Externí odkaz:
https://doaj.org/article/ddad26b063a74949a1af90fcb01bd10e
Autor:
Dominik F. Draxler, Justine Brodard, Björn Zante, Stephan M. Jakob, Jan Wiegand, Johanna A. Kremer Hovinga, Anne Angelillo-Scherrer, Alicia Rovo
Publikováno v:
Thrombosis Journal, Vol 20, Iss 1, Pp 1-6 (2022)
Abstract In Covid-19, anticoagulation with heparin is often administered to prevent or treat thromboembolic events. Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin treatment, caused by heparin-dependent, platelet activating
Externí odkaz:
https://doaj.org/article/8f406d3a1775494caaa506395308baff
Autor:
Andrea Ruberti, Johanna A. Kremer Hovinga, Federico Nappi, Aurora Vettese, Elena Bianchi, Eliana Fernandes, Elena Galfetti, Rita Monotti, Pamella Paul, Stefano Regazzoni, Daniela Valente, Davide Rossi, Georg Stussi, Bernhard Gerber
Publikováno v:
Swiss Medical Weekly, Vol 153, Iss 3 (2023)
AIMS OF THE STUDY: Acquired haemophilia A is a rare disease with an annual incidence of 1.48 per million. Based on clinical observations, we suspect a higher incidence in southern Switzerland, and aimed at providing local epidemiological data, and cl
Externí odkaz:
https://doaj.org/article/b9cd8e6b1af4463c9eb5e55afec7ae86
Autor:
Henning Nilius, Adam Cuker, Sigve Haug, Christos Nakas, Jan-Dirk Studt, Dimitrios A. Tsakiris, Andreas Greinacher, Adriana Mendez, Adrian Schmidt, Walter A. Wuillemin, Bernhard Gerber, Johanna A. Kremer Hovinga, Prakash Vishnu, Lukas Graf, Alexander Kashev, Raphael Sznitman, Tamam Bakchoul, Michael Nagler
Publikováno v:
EClinicalMedicine, Vol 55, Iss , Pp 101745- (2023)
Summary: Background: Diagnosing heparin-induced thrombocytopenia (HIT) at the bedside remains challenging, exposing a significant number of patients at risk of delayed diagnosis or overtreatment. We hypothesized that machine-learning algorithms could
Externí odkaz:
https://doaj.org/article/abfa12e6d5a74c3790cf25650e4523cd
Autor:
Özgür Pektaş, Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knöbl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga, Jessica Minkue Mi Edou, Rui de Passos Sousa, Sriya Gunawardena, Julie Lin
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 44, Iss , Pp S33-S34 (2022)
Objective: The efficacy and safety of caplacizumab (CPLZ) for patients (pts) with immune-mediated thrombotic thrombocytopenic purpura (iTTP; also known as acquired TTP) were demonstrated in the Phase 3 HERCULES trial, with a 28-day follow-up period a
Externí odkaz:
https://doaj.org/article/3d490432b75848c89fb22178c2f0fde8
Autor:
Vanessa Alexandra Buetler, Nada Agbariah, Deborah Pia Schild, Fabian D. Liechti, Anna Wieland, Nicola Andina, Felix Hammann, Johanna A. Kremer Hovinga
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
IntroductionAn increasing number of case reports have associated vaccinations against coronavirus disease 2019 (COVID-19) with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a very rare but potentially life-threatening thrombotic microan
Externí odkaz:
https://doaj.org/article/35b0b6bcd0bf4d2892465037de8d7d22
Autor:
Katarzyna A. Jalowiec, Martin Andres, Behrouz Mansouri Taleghani, Albulena Musa, Martina Dickenmann, Anne Angelillo-Scherrer, Alicia Rovó, Johanna A. Kremer Hovinga
Publikováno v:
Journal of Medical Case Reports, Vol 14, Iss 1, Pp 1-6 (2020)
Abstract Background Acquired hemophilia A is a rare autoimmune disease with clinically often significant bleeding diathesis resulting from circulating autoantibodies inhibiting coagulation factor VIII. Half of acquired hemophilia A cases are associat
Externí odkaz:
https://doaj.org/article/837b7bccee324057b84917eaa64503aa
Publikováno v:
HemaSphere, Vol 5, Iss 11, p e647 (2021)
Externí odkaz:
https://doaj.org/article/91dd103fd2544fbc970daf5a248e2112
Autor:
Flora Peyvandi, Spero Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Filip Callewaert, Hilde De Winter
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S46-S47 (2021)
Objective: An integrated analysis based on the Phase 2 TITAN (NCT01151423) and Phase 3 HERCULES (NCT02553317) studies with caplacizumab (CPLZ) in acquired thrombotic thrombocytopenic purpura (aTTP) was performed to assess treatment differences on eff
Externí odkaz:
https://doaj.org/article/50e75989ab3e4389a9bb0fcf5b02f584